glp 1 agonist nash Resmetirom and GLP-1 agonists for MASH: complementary rather than exclusive Resolution of NASH and hepatic
Description
Liu Z-Z, Duan X-X, Yuan M-C, Yu J, Hu X, Han X, et al
Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients With Type 2 Diabetes (SURPASS-1): A Double-Blind, Randomised, Phase 3 Trial
2023), whereas cognitive advantages shown in diabetic individuals indicate a possible preventive effect against Alzheimer's in high-risk groups (Athauda et al
The LEAN trial with liraglutide and a phase 2 trial of semaglutide in patients with non-alcoholic steatohepatitis (NASH) showed improvements in liver histology and reductions in hepatic inflammation markers
